Plus Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Plus Therapeutics reports significant net losses and going concern doubts for fiscal year 2025, while advancing its CNS cancer radiopharmaceutical and diagnostic pipeline with key clinical milestones and commercial agreements.
NASDAQ
Plus Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include information previously omitted from Part III, Items 10 through 14, and updates the exhibit list and share outstanding information.
NASDAQ
10-K: Plus Therapeutics Reports 2024 Results, Highlights Clinical Progress and Strategic Initiatives
Plus Therapeutics' 2024 10-K filing details ongoing clinical trials for REYOBIQ, acquisition of the CNSide Platform, and efforts to secure additional funding amidst financial uncertainties.
NASDAQ
Plus Therapeutics' annual 10-K filing highlights the company's continued losses, reliance on external funding, and strategic focus on developing targeted radiotherapeutics for central nervous system cancers.